首页 | 本学科首页   官方微博 | 高级检索  
检索        

弥漫大B细胞淋巴瘤化疗耐药与细胞因子白细胞介素-6、-10水平的相关性
引用本文:许晓强,张巧花,侯淑玲,白林海.弥漫大B细胞淋巴瘤化疗耐药与细胞因子白细胞介素-6、-10水平的相关性[J].白血病.淋巴瘤,2010,19(10):604-606.
作者姓名:许晓强  张巧花  侯淑玲  白林海
作者单位:山西医科大学研究生院,太原,030001;山西省肿瘤医院血液科,太原,030001;山西省汾阳医院血液科,太原,030001
摘    要: 目的 探讨弥漫大B细胞淋巴瘤(DLBCL)患者血清细胞因子白细胞介素(IL)-2、IL-6、IL-8、IL-10、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)表达水平与化疗耐药之间的相关性。方法 30例DLBCL化疗耐药患者为化疗耐药组,30例DLBCL化疗敏感患者为化疗敏感组,20名健康人作为健康对照组,ELISA法测定两组DLBCL患者治疗前、中、后及对照组血清中IL-2、IL-6、IL-8、IL-10、TNF-α、IFN-γ水平。结果 化疗耐药组患者血清中的IL-6、IL-10治疗前表达水平明显高于化疗敏感组患者治疗前和对照组表达水平(P值均<0.05),治疗缓解后明显低于治疗前(P=0.02、P=0.015)。DLBCL复发耐药时,患者血清中的IL-6、IL-10又高于缓解时水平(P=0.004、P<0.001)。化疗耐药组Ⅲ~Ⅳ期患者治疗前IL-6水平明显高于Ⅰ~Ⅱ期患者(P<0.05)。其他细胞因子IL-2、IL-8、TNF-α、IFN-γ水平在化疗耐药组、化疗敏感组、对照组之间差异无统计学意义(P>0.05)。结论 DLBCL患者血清中的IL-6、IL-10表达水平的高低与DLBCL化疗疗效密切相关,可能与DLBCL细胞耐药有关。

关 键 词:淋巴瘤  大细胞  弥漫型  细胞因子类  药物疗法  抗药性  肿瘤
收稿时间:2010-01-28;

Correlation between the chemotherapy resistance of diffuse large B-cell lymphoma and cytokines IL-6 and IL-10
XU Xiao-qiang,ZHANG Qiao-hua,HOU Shu-ling,BAI Lin-hai.Correlation between the chemotherapy resistance of diffuse large B-cell lymphoma and cytokines IL-6 and IL-10[J].Journal of Leukemia & Lymphoma,2010,19(10):604-606.
Authors:XU Xiao-qiang  ZHANG Qiao-hua  HOU Shu-ling  BAI Lin-hai
Institution:. (Department of Postgraduate, Shanxi Medical University, Taiyuan 030001, China)
Abstract:Objective To investigate the correlation between expression levels of serum cytokines IL-2,IL-6, IL-8, IL-10, TNF-α and IFN-γ in patients with diffuse large B-cell lymphoma(DLBCL) and chemotherapy resistance. Methods 30 cases of DLBCL patients with chemotherapy resistant, 30 cases of DLBCL patients with chemotherapy sensitive and 20 cases of healthy individuals as normal control group were enrolled. The levels of serum cytokines IL-2, IL-6, IL-8, IL-10, TNF-α and IFN-γbefore, during and after treatment in both DLBCL groups and normal control group were detected by ELISA assay. Results The expression level of serum IL-6 and IL-10 before treatment in DLBCL patients with chemotherapy resistance was significantly higher than that in DLBCL patients with chemotherapy sensitive and normal control group (P < 0.05), however,that after treatment in DLBCL patients with chemotherapy resistance was significantly lower than that before treatment (P = 0.02, P = 0.015). The level of serum IL-6 and IL-10 in patients with DLBCL recurrence into drug resistance was higher than that during of remission (P = 0.004, P <0.001). Before treatment, the expression level of serum IL-6 in patients with Ⅲ-Ⅳ stage in chemotherapy resistant group was significantly higher than that in ones with Ⅰ - Ⅱ stage(P <0.05). Levels of IL-2, IL-8, TNF-α and IFN-γin chemotherapy resistant group, chemotherapy sensitive group and the normal control group were no differences (P >0.05).Conclusion The expression levels of the serum IL-6 and IL-10 were closely correlated with the chemotherapy efficacy of DLBCL, they may be involved in drug resistance of DLBCL.
Keywords:Lymphoma  large-cell  diffuse  Cytokines  Drug therapy  Drug resistance  neoplasms
本文献已被 维普 万方数据 等数据库收录!
点击此处可从《白血病.淋巴瘤》浏览原始摘要信息
点击此处可从《白血病.淋巴瘤》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号